Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
94 hedge funds and large institutions have $200M invested in Taro Pharmaceutical Industries Ltd. in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 16 closing their positions.
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
11% more call options, than puts
Call options by funds: $296K | Put options by funds: $267K
4% more funds holding
Funds holding: 90 → 94 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $203M → $200M (-$2.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.63M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$4.01M |
| 3 |
Millennium Management
New York
|
+$3.35M |
| 4 |
Squarepoint
New York
|
+$912K |
| 5 |
CL
CSS LLC
Chicago,
Illinois
|
+$882K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.21M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$8.08M |
| 3 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$4.79M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.35M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.1M |
TARO Hedge Fund Activity: Q1 2024 in Review
94 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q1 2024, worth a combined $200M — down 1.4% from $203M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TARO positions and 16 closed out — a net gain of 4 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $9.63M. The largest seller was Invesco, cutting an estimated $9.21M.
- 94 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q1 2024, up from 90 in Q4 2023.
- Funds reported $200M of Taro Pharmaceutical Industries Ltd. stock for Q1 2024, down 1.4% quarter-over-quarter.
- 20 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q1 2024 and 16 closed out, a net change of +4 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q1 2024 was Qube Research & Technologies (QRT), an estimated $9.63M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q1 2024 was Invesco, an estimated $9.21M sold.
Based on aggregated 13F filings for Q1 2024.